KUALA LUMPUR, 8 JULY 2021 – Ho Wah Genting Berhad’s wholly-owned subsidiary, HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) joint venture partner, US-based E-MO Biology Inc.’s COVID-19 study results was recently posted on medRxiv, an online archive platform for preprints manuscripts in the medical, clinical, and related health sciences field.
The article entitled “Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2” can be viewed here.
The completed clinical trial which uses Poliovirus vaccination to help with the protection from SARS-CoV-2 showed promising results.
The study’s results exhibited similarities between the poliovirus RdRP and SARS-CoV-2 RdRp structures, indicating the potential protection against SARS-CoV-2 that may be provided by the poliovirus vaccination.
HWGB Biotech’s General Manager (Medical & Pharmaceutical Research), Dr. Yaman Walid Kassab said, "The results published show valuable findings and reflect significant progress.. We look forward to continuing the momentum towards our goal of providing a safe and affordable COVID-19 vaccine to the public."
***